Effects of low-flux and high-flux hemodialysis on the survival of elderly maintenance hemodialysis patients

References

• Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015;385(9981):1975–1982. doi: 10.1016/S0140-6736(14)61601-9.
   PubMed Web of Science ®Google Scholar
• Collins AJ, Kasiske B, Herzog C, et al. Excerpts from the United States renal data system 2003 annual data report: atlas of end-stage renal disease in the United States. Am J Kidney Dis. 2005;45(1, supplement 1):A5–A7. doi: 10.1053/j.ajkd.2004.10.009.
   PubMed Web of Science ®Google Scholar
• Sun L, Zou L-X, Han Y-C, et al. Forecast of the incidence, prevalence and burden of end-stage renal disease in Nanjing, China to the year 2025. BMC Nephrol. 2016;17(1):60. doi: 10.1186/s12882-016-0269-8.
   PubMedGoogle Scholar
• Mccullough KP, Morgenstern H, Saran R, et al. Projecting ESRD incidence and prevalence in the United States through 2030. J Am Soc Nephrol. 2019; 30(1):127–135. doi: 10.1681/ASN.2018050531.
   PubMed Web of Science ®Google Scholar
• Dikow R, Zeier M, Ritz E. Cardiovascular abnormalities and hypertension in the elderly dialysis patient. Semin Dial. 2002;15(2):121–126. doi: 10.1046/j.1525-139x.2002.00037.x.
   PubMed Web of Science ®Google Scholar
• Canaud B, Tong L, Tentori F, et al. Clinical practices and outcomes in elderly hemodialysis patients: results from the dialysis outcomes and practice patterns study (DOPPS). Clin J Am Soc Nephrol. 2011;6(7):1651–1662. doi: 10.2215/CJN.03530410.
   PubMed Web of Science ®Google Scholar
• Couchoud C, Labeeuw M, Moranne O, et al.; French Renal Epidemiology and Information Network (REIN) registry. A clinical score to predict 6-month prognosis in elderly patients starting dialysis for end-stage renal disease. Nephrol Dial Transplant. 2009;24(5):1553–1561. doi: 10.1093/ndt/gfn698.
   PubMed Web of Science ®Google Scholar
• Murtagh FEM, Marsh JE, Donohoe P, et al. Dialysis or not? A comparative survival study of patients over 75 years with chronic kidney disease stage 5. Nephrol Dial Transplant. 2007;22(7):1955–1962. doi: 10.1093/ndt/gfm153.
   PubMed Web of Science ®Google Scholar
• Berger JR, Jaikaransingh V, Hedayati SS. End-stage kidney disease in the elderly: approach to dialysis initiation, choosing modality, and predicting outcomes. Adv Chronic Kidney Dis. 2016;23(1):36–43. doi: 10.1053/j.ackd.2015.08.005.
   PubMed Web of Science ®Google Scholar
• Von Albertini B, Miller JH, Gardner PW, et al. High-flux hemodiafiltration: under six hours/week treatment. Trans Am Soc Artif Intern Organs. 1984;30(1):227–231.
   PubMedGoogle Scholar
• Götz AK, Böger CA, Popal M, et al. Effect of membrane flux and dialyzer biocompatibility on survival in end-stage diabetic nephropathy. Nephron Clin Pract. 2008;109(3):c154–c160. doi: 10.1159/000145459.
   PubMedGoogle Scholar
• Asci G, Tz H, Ozkahya M, et al. The impact of membrane permeability and dialysate purity on cardiovascular outcomes. J Am Soc Nephrol. 2013; 24(6):1014–1023. doi: 10.1681/ASN.2012090908.
   PubMed Web of Science ®Google Scholar
• Tattersall J, Martin-Malo A, Pedrini L, et al. EBPG guideline on dialysis strategies. Nephrol Dial Transplant. 2007;22(Suppl 2):ii5–21. doi: 10.1093/ndt/gfm022.
   Web of Science ®Google Scholar
• Cheung AK, Levin NW, Greene T, et al. Effects of high-flux hemodialysis on clinical outcomes: results of the HEMO study. J Am Soc Nephrol. 2003;14(12):3251–3263. doi: 10.1097/01.asn.0000096373.13406.94.
   PubMed Web of Science ®Google Scholar
• Chauveau P, Nguyen H, Combe C, et al. Dialyzer membrane permeability and survival in hemodialysis patients. Am J Kidney Dis. 2005;45(3):565–571. doi: 10.1053/j.ajkd.2004.11.014.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Martin-Malo A, Hannedouche T, et al. Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol. 2009; 20(3):645–654. doi: 10.1681/ASN.2008060590.
   PubMed Web of Science ®Google Scholar
• Wanner C, Krane V, März W, et al. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. Kidney Blood Press Res. 2004;27(4):259–266. doi: 10.1159/000080241.
   PubMed Web of Science ®Google Scholar
• Sánchez-Álvarez E, Rodríguez-García M, Locatelli F, et al. Survival with low-and high-flux dialysis. Clin Kidney J. 2021;14(8):1915–1923. doi: 10.1093/ckj/sfaa233.
   PubMed Web of Science ®Google Scholar
• Palmer SC, Rabindranath KS, Craig JC, et al. High-flux versus low-flux membranes for end-stage kidney disease. Cochrane Database Syst Rev. 2012;2012(9):CD005016. doi: 10.1002/14651858.CD005016.pub2.
   PubMedGoogle Scholar
• Zhao F, Wang Z, Liu L, et al. The influence of mortality rate from membrane flux for end-stage renal disease: a meta-analysis. Nephrol Ther. 2016;13(1):9–13. doi: 10.1016/j.nephro.2016.07.445.
   PubMed Web of Science ®Google Scholar
• K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1): S1–S266.
   PubMed Web of Science ®Google Scholar
• Gotch FA, Sargent JA. A mechanistic analysis of the national cooperative dialysis study (NCDS). Kidney Int. 1985;28(3):526–534. doi: 10.1038/ki.1985.160.
   PubMed Web of Science ®Google Scholar
• Mandolfo S, Malberti F, Imbasciati E, et al. Impact of blood and dialysate flow and surface on performance of new polysulfone hemodialysis dialyzers. Int J Artif Organs. 2003;26(2):113–120. doi: 10.1177/039139880302600204.
   PubMed Web of Science ®Google Scholar
• Michaels AS. Operating parameters and performance criteria for hemodialyzers and other membrane-separation devices. Trans Am Soc Artif Intern Organs. 1966;12:387–392.
   PubMedGoogle Scholar
• Daugirdas JT, Depner TA. A nomogram approach to hemodialysis urea modeling. Am J Kidney Dis. 1994;23(1):33–40. doi: 10.1016/s0272-6386(12)80809-2.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Manzoni C, Di Filippo S. The importance of convective transport. Kidney Int Suppl. 2002;61(80):115–120. doi: 10.1046/j.1523-1755.61.s80.21.x.
   Google Scholar
• Saran R, Canaud BJ, Depner TA, et al. Dose of dialysis: key lessons from major observational studies and clinical trials. Am J Kidney Dis. 2004;44(5 Suppl 2):47–53. doi: 10.1016/S0272-6386(04)01105-9.
   PubMed Web of Science ®Google Scholar
• Locatelli F. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2003;348(15):1491–1494.
   PubMedGoogle Scholar
• Vanholder R, De Smet R, Glorieux G, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003;63(5):1934–1943. doi: 10.1046/j.1523-1755.2003.00924.x.
   PubMed Web of Science ®Google Scholar
• Chertow GM, Owen WF, Lazarus JM, et al. Exploring the reverse J-shaped curve between urea reduction ratio and mortality. Kidney Int. 1999;56(5):1872–1878. doi: 10.1046/j.1523-1755.1999.00734.x.
   PubMed Web of Science ®Google Scholar
• Clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis. 2006;48:S2–S90. doi: 10.1053/j.ajkd.2006.03.051.
   PubMedGoogle Scholar
• Tattersall J, Farrington K, Gentile G, et al. Is Kt/V useful in elderly dialysis patients? Pro and con arguments. Nephrol Dial Transplant. 2018;33(5):742–750. doi: 10.1093/ndt/gfy042.
   PubMed Web of Science ®Google Scholar
• Çelik G, Oc B, Kara I, et al. Comparison of nutritional parameters among adult and elderly hemodialysis patients. Int J Med Sci. 2011;8(7):628–634. doi: 10.7150/ijms.8.628.
   PubMed Web of Science ®Google Scholar
• Park J-S, Kim G-H, Kang CM, et al. Application of cystatin C reduction ratio to high-flux hemodialysis as an alternative indicator of the clearance of middle molecules. Korean J Intern Med. 2010; 25(1):77–81. doi: 10.3904/kjim.2010.25.1.77.
   PubMedGoogle Scholar
• Zimbudzi E, Samlero R, Kerr PG, et al. How much is enough? An investigation of the relationship between haemodialysis adequacy and quality of life of elderly patients. Nephrology . 2016;21(4):314–320. doi: 10.1111/nep.12594.
   PubMed Web of Science ®Google Scholar
• Foley RN, Parfrey PS, Harnett JD, et al . The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis. 1996;28(1):53–61. doi: 10.1016/s0272-6386(96)90130-4.
   Google Scholar
• Pisoni RL, Bragg-Gresham JL, Young EW, et al. Anemia management and outcomes from 12 countries in the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis. 2004;44(1):94–111. doi: 10.1053/j.ajkd.2004.03.023.
   PubMed Web of Science ®Google Scholar
• Hanafusa N, Nomura T, Hasegawa T, et al. Age and anemia management: relationship of hemoglobin levels with mortality might differ between elderly and nonelderly hemodialysis patients. Nephrol Dial Transplant. 2014;29(12):2316–2326. doi: 10.1093/ndt/gfu272.
   PubMed Web of Science ®Google Scholar
• Silverberg DS, Wexler D, Blum M, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000; Jun35(7):1737–1744. doi: 10.1016/s0735-1097(00)00613-6.
   PubMed Web of Science ®Google Scholar
• Ayli D, Ayli M, Azak A, et al. The effect of high-flux hemodialysis on renal anemia. Journal of Nephrology. 2004;17(5):701–706.
   PubMed Web of Science ®Google Scholar
• El-Wakil HS, Abou-Zeid AA, El-Gohary IE, et al. Relation of Middle molecules levels and oxidative stress to erythropoietin requirements in high-flux versus low-flux hemodialysis. Saudi J Kidney Dis Transpl. 2013;24(5):930–937. doi: 10.4103/1319-2442.118082.
   PubMedGoogle Scholar
• He L, Fu M, Chen X, et al. Effect of dialysis dose and membrane flux on hemoglobin cycling in hemodialysis patients. Hemodial Int. 2015;19(2):263–269. doi: 10.1111/hdi.12215.
   PubMed Web of Science ®Google Scholar
• de Jager DJ, Grootendorst DC, Jager KJ, et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. Jama. 2009;302(16):1782–1789. doi: 10.1001/jama.2009.1488.
   PubMed Web of Science ®Google Scholar
• Churchill DN, Taylor W, Tomlinson CW, et al. Effect of high-flux hemodialysis on cardiac structure and function among patients with end-stage renal failure. Nephron. 1993;65(4):573–577. doi: 10.1159/000187566.
   PubMed Web of Science ®Google Scholar
• Fujii H, Nakai K, Goto S, et al. Clinical characteristics of very elderly patients at hemodialysis initiation. Intern Med. 2015;54(6):579–583. doi: 10.2169/internalmedicine.54.3672.
   PubMed Web of Science ®Google Scholar
• Huang SHS, Filler G, Lindsay R, et al. Euvolemia in hemodialysis patients: a potentially dangerous goal? Semin Dial. 2015;28(1):1–5. doi: 10.1111/sdi.12317.
   PubMed Web of Science ®Google Scholar
• Scheuer J, Stezoski SW. The effects of uremic compounds on cardiac function and metabolism. J Mol Cell Cardiol. 1973;5(3):287–300. doi: 10.1016/0022-2828(73)90068-0.
   PubMed Web of Science ®Google Scholar
• Chazot C, Kirchgessner J, Pham J, et al. Effect of membrane permeability on cardiovascular risk factors and β2m plasma levels in patients on long-term haemodialysis: a randomised crossover trial. Nephron. 2015;129(4):269–275. doi: 10.1159/000380767.
   PubMed Web of Science ®Google Scholar